Thursday, Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved the company's ready-to-use romidepsin injection solution.
The product is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy.
Following this approval, romidepsin injection solution is now eligible for Competitive Generic Therapy designation, which provides Amneal with 180 days of market exclusivity.
The approval also reflects the company's continued focus on addressing meaningful needs for hospitals and providers.
In the pre-market hours, AMRX is trading at $13.19, up 2.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.